PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...

The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management. The medication is now cleared by the FDA for clinical use in perioperative settings, ...

Detailed price information for Pharmather Hldgs Ltd (PHRM-CN) from The Globe and Mail including charting and trades.

The latest announcement is out from PharmaTher Holdings Ltd ( ($TSE:PHRM) ). PharmaTher Holdings Ltd. has received FDA approval for its ketamine ...

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...

"PharmaTher is committed to revolutionizing patient care through ketamine. With KetaVault™, PharmaTher isn't just sharing data; we're igniting a new era of collaborative ketamine innovation.

--PharmaTher Holdings Ltd., a specialty psychedelic pharmaceutical company, today announced it submitted an Investigational New Drug application with the U.S. Food and Drug Administration for the ...

PharmaTher recently entered into a researcher collaboration agreement with its MN-Patch technology with Revive Therapeutics Ltd. to evaluate the delivery of 3,4-Methylenedioxy methamphetamine (MDMA).

PharmaTher Holdings Ltd. PHRRF PHRM is focused on the research, development and commercialization of specialty ketamine prescription-based products including KETAPATCH, a ketamine microneedle ...

PharmaTher Holdings Ltd. PHRRF has published its operational and audited financial results for fiscal year ended May 31, 2022. The company, which focuses on delivering ketamine for treating mental ...